These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18703527)

  • 1. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
    Phillips DR; Hay P
    J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to combating lipoatrophy: do they work?
    Martin A; Mallon PW
    J Antimicrob Chemother; 2005 May; 55(5):612-5. PubMed ID: 15761072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
    Mallewa JE; Wilkins E; Vilar J; Mallewa M; Doran D; Back D; Pirmohamed M
    J Antimicrob Chemother; 2008 Oct; 62(4):648-60. PubMed ID: 18565973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of facial lipoatrophy via autologous fat transfer.
    Cohen G; Treherne A
    J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-associated lipodystrophy syndrome.
    Milinković A
    Coll Antropol; 2006 Dec; 30 Suppl 2():59-62. PubMed ID: 17508476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
    Kong HH; Myers SA
    Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
    Hirsch HH; Battegay M
    Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-associated facial lipoatrophy--review of current therapy options.
    Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
    Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.